IN2014CH00391A - - Google Patents

Info

Publication number
IN2014CH00391A
IN2014CH00391A IN391CH2014A IN2014CH00391A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A IN 391CH2014 A IN391CH2014 A IN 391CH2014A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A
Authority
IN
India
Prior art keywords
cellular immunity
peptide
cancer
composition
subject
Prior art date
Application number
Other languages
English (en)
Inventor
Katsuyuki Okubo
Yoshiki Maeda
Arimichi Okazaki
Daisuke Asari
takuya Shishido
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00391A publication Critical patent/IN2014CH00391A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN391CH2014 2013-02-05 2014-01-29 IN2014CH00391A (enrdf_load_stackoverflow)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020906 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00391A true IN2014CH00391A (enrdf_load_stackoverflow) 2015-04-03

Family

ID=50028737

Family Applications (1)

Application Number Title Priority Date Filing Date
IN391CH2014 IN2014CH00391A (enrdf_load_stackoverflow) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US10449144B2 (enrdf_load_stackoverflow)
EP (1) EP2762159A1 (enrdf_load_stackoverflow)
JP (1) JP6512568B2 (enrdf_load_stackoverflow)
KR (1) KR20140100419A (enrdf_load_stackoverflow)
CN (1) CN103961307B (enrdf_load_stackoverflow)
CA (1) CA2841016A1 (enrdf_load_stackoverflow)
IN (1) IN2014CH00391A (enrdf_load_stackoverflow)
RU (1) RU2687144C2 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP2868325B1 (en) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
WO2014113490A2 (en) 2013-01-15 2014-07-24 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
AU2014231816B2 (en) 2013-03-12 2016-11-03 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
CN106687138B (zh) * 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
RU2017115114A (ru) * 2014-10-02 2018-11-05 Нитто Денко Корпорейшн Фармацевтическая композиция вакцины для чрескожного введения

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CN100408683C (zh) * 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
US7378384B2 (en) 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
JP4621142B2 (ja) 2003-11-05 2011-01-26 株式会社癌免疫研究所 Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
PT1961761E (pt) 2005-11-30 2010-12-16 Chugai Pharmaceutical Co Ltd Novos compostos peptídicos do tumor de wilms
AU2006321287B2 (en) * 2005-12-01 2013-05-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
CA2886551A1 (en) 2006-02-22 2007-08-30 Haruo Sugiyama Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) * 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
NZ592509A (en) 2006-12-28 2012-11-30 Int Inst Cancer Immunology Inc HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
JP5478260B2 (ja) * 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011046832A2 (en) 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US20140220058A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
EP2762158A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
JP6473292B2 (ja) 2013-02-05 2019-02-20 日東電工株式会社 ワクチン組成物

Also Published As

Publication number Publication date
JP2014169277A (ja) 2014-09-18
US20140220055A1 (en) 2014-08-07
JP6512568B2 (ja) 2019-05-15
CA2841016A1 (en) 2014-08-05
US10449144B2 (en) 2019-10-22
CN103961307B (zh) 2019-11-29
RU2014102936A (ru) 2015-08-10
RU2687144C2 (ru) 2019-05-07
CN103961307A (zh) 2014-08-06
EP2762159A1 (en) 2014-08-06
KR20140100419A (ko) 2014-08-14

Similar Documents

Publication Publication Date Title
IN2014CH00391A (enrdf_load_stackoverflow)
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
MX371187B (es) Péptidos terapéuticos.
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
IN2014CH00395A (enrdf_load_stackoverflow)
IN2014CH00393A (enrdf_load_stackoverflow)
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
IN2014CH00396A (enrdf_load_stackoverflow)
MX386234B (es) Vacuna para la malaria.
SG10201903119QA (en) Polypeptide vaccine
MX377729B (es) Métodos para tratamiento del melanoma.
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
SG10201808746QA (en) Methods for enhancing the efficacy of a tumor-directed immune response
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MY191539A (en) Streptococcal vaccine
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
ZA202503387B (en) Semaglutide in medical therapy
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors